{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:12:46Z","timestamp":1790835166812,"version":"4.1.0"},"reference-count":120,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The myelodysplastic syndromes (MDSs) constitute a profoundly heterogeneous myeloid malignancy with a common origin in the hemopoietic stem cell compartment. Consequently, patient management and treatment are as heterogeneous. Decision-making includes identifying risk, symptoms, and options for an individual and conducting a risk-benefit analysis. The only potential cure is allogeneic stem cell transplantation, and albeit the fraction of patients with MDS who undergo transplant increase over time because of better management and increased donor availability, a majority are not eligible for this intervention. Current challenges encompass to decrease the relapse risk, the main cause of hematopoietic stem cell transplantation failure. Hypomethylating agents (HMAs) constitute firstline treatment for higher-risk MDSs. Combinations with other drugs as firstline treatment has, to date, not proven more efficacious than monotherapy, although combinations approved for acute myeloid leukemia, including venetoclax, are under evaluation and often used as rescue treatment. The treatment goal for lower-risk MDS is to improve cytopenia, mainly anemia, quality of life, and, possibly, overall survival. Erythropoiesis-stimulating agents (ESAs) constitute firstline treatment for anemia and have better and more durable responses if initiated before the onset of a permanent transfusion need. Treatment in case of ESA failure or ineligibility should be tailored to the main disease mechanism: immunosuppression for hypoplastic MDS without high-risk genetics, lenalidomide for low-risk del(5q) MDS, and luspatercept for MDS with ring sideroblasts. Approved therapeutic options are still scarcer for MDS than for most other hematologic malignancies. Better tools to match disease biology with treatment, that is, applied precision medicines are needed to improve patient outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023020079","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T15:10:57Z","timestamp":1698160257000},"page":"2268-2281","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":46,"title":["Clinical decision-making and treatment of myelodysplastic syndromes"],"prefix":"10.1182","volume":"142","author":[{"given":"Eva S.","family":"Hellstr\u00f6m-Lindberg","sequence":"first","affiliation":[{"name":"1Department of Medicine, Karolinska Institutet, Center for Hematology and Regenerative Medicine, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[{"name":"2Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2023122816270914400_bib1","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s41375-018-0089-x","article-title":"Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study","volume":"32","author":"Stauder","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"2023122816270914400_bib2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/joim.13535","article-title":"Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia","volume":"292","author":"Woll","year":"2022","journal-title":"J\u00a0Intern Med"},{"issue":"16","key":"2023122816270914400_bib3","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.3390\/cancers13164116","article-title":"Nature or nurture? Role\u00a0of the bone marrow microenvironment in the genesis and maintenance of myelodysplastic syndromes","volume":"13","author":"Mian","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2023122816270914400_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndroms","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"7","key":"2023122816270914400_bib5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2023122816270914400_bib6","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"26","key":"2023122816270914400_bib118","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/blood.2023020078","article-title":"Diagnosis and classification of myelodysplastic syndromes","volume":"142","author":"Hasserjian","year":"2023","journal-title":"Blood"},{"issue":"26","key":"2023122816270914400_bib119","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood.2023022222","article-title":"Causes and consequences of clonal hematopoiesis","volume":"142","author":"Weeks","year":"2023","journal-title":"Blood"},{"issue":"26","key":"2023122816270914400_bib120","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1182\/blood.2023020081","article-title":"The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes","volume":"142","author":"DeZern","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2023122816270914400_bib7","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41409-022-01582-0","article-title":"Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study","volume":"57","author":"Lindholm","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2023122816270914400_bib8","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/bjh.15243","article-title":"Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register","volume":"181","author":"Moreno Berggren","year":"2018","journal-title":"Br J Haematol"},{"issue":"23","key":"2023122816270914400_bib9","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","article-title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes","volume":"25","author":"Malcovati","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023122816270914400_bib10","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMp048266","article-title":"Myelodysplastic syndromes--coping with ineffective hematopoiesis","volume":"352","author":"Cazzola","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023122816270914400_bib11","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3324\/haematol.2018.212217","article-title":"Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes","volume":"105","author":"de Swart","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"2023122816270914400_bib12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0609.2011.01654.x","article-title":"Quality of life, physical function and MRI T2\u2217 in elderly low-risk MDS patients treated to a haemoglobin level of &gt;\/=120 g\/L with darbepoetin alfa\u00a0+\/- filgrastim or erythrocyte transfusions","volume":"87","author":"Nilsson-Ehle","year":"2011","journal-title":"Eur J Haematol"},{"issue":"suppl 1","key":"2023122816270914400_bib13","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.1182\/blood-2022-155811","article-title":"Transfusion patterns during early follow-up predict overall survival independently of IPSS-M in patients with myelodysplastic syndromes [abstract]","volume":"140","author":"Creignou","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2023122816270914400_bib14","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1038\/s41375-020-01022-2","article-title":"Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome","volume":"35","author":"Hoeks","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"2023122816270914400_bib15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M19-0916","article-title":"Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes: a randomized trial","volume":"172","author":"Angelucci","year":"2020","journal-title":"Ann Intern Med"},{"issue":"3","key":"2023122816270914400_bib16","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3324\/haematol.2018.212332","article-title":"Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry","volume":"105","author":"Hoeks","year":"2020","journal-title":"Haematologica"},{"key":"2023122816270914400_bib17","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3389\/fimmu.2020.00586","article-title":"Association of serum ferritin levels before start of conditioning with mortality after alloSCT - a prospective, non-interventional study of the EBMT Transplant Complications Working Party","volume":"11","author":"Penack","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"2023122816270914400_bib18","doi-asserted-by":"crossref","first-page":"42.e1","DOI":"10.1016\/j.jtct.2022.10.002","article-title":"Iron chelation with deferasirox suppresses the appearance of labile plasma iron during conditioning chemotherapy prior to allogeneic stem cell transplantation","volume":"29","author":"Essmann","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2023122816270914400_bib19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2023122816270914400_bib20","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood-2018-06-857102","article-title":"Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"issue":"17","key":"2023122816270914400_bib21","first-page":"2047","article-title":"Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2023122816270914400_bib22","doi-asserted-by":"crossref","first-page":"e631","DOI":"10.1097\/HS9.0000000000000631","article-title":"EHA endorsement of the European guidelines for myelodysplastic syndromes, MDS-RIGHT","volume":"5","author":"Blum","year":"2021","journal-title":"Hemasphere"},{"issue":"12","key":"2023122816270914400_bib23","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1038\/s41375-018-0118-9","article-title":"A\u00a0phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-alpha in anemic patients with low-risk MDS","volume":"32","author":"Fenaux","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"2023122816270914400_bib24","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/leu.2017.192","article-title":"A\u00a0phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes","volume":"31","author":"Platzbecker","year":"2017","journal-title":"Leukemia"},{"issue":"21","key":"2023122816270914400_bib25","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2007.15.4906","article-title":"Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome","volume":"26","author":"Jadersten","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023122816270914400_bib26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/bjh.15707","article-title":"Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low-\u00a0and intermediate-1-risk myelodysplastic syndrome: a systematic literature review","volume":"184","author":"Park","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"2023122816270914400_bib27","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/joim.12579","article-title":"Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome","volume":"281","author":"Garelius","year":"2017","journal-title":"J\u00a0Intern Med"},{"key":"2023122816270914400_bib28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/01.HS9.0000843564.40783.b4","article-title":"S168: erythropoietin stimulation agents significantly improves outcome in lower risk MDS","volume":"6","author":"Garelius","year":"2022","journal-title":"HemaSphere"},{"issue":"16","key":"2023122816270914400_bib29","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1182\/bloodadvances.2022007858","article-title":"The extent of residual WT HSPCs is associated with the degree of anemia in patients with SF3B1-mutated MDS-RS","volume":"6","author":"Hofman","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2023122816270914400_bib30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood.V92.1.68.413k23_68_75","article-title":"Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients","volume":"92","author":"Hellstrom-Lindberg","year":"1998","journal-title":"Blood"},{"issue":"2","key":"2023122816270914400_bib31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood-2003-07-2252","article-title":"Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial","volume":"104","author":"Casadevall","year":"2004","journal-title":"Blood"},{"issue":"10","key":"2023122816270914400_bib32","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1182\/blood.V87.10.4076.bloodjournal87104076","article-title":"Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in\u00a0vivo synergy","volume":"87","author":"Negrin","year":"1996","journal-title":"Blood"},{"issue":"3","key":"2023122816270914400_bib33","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1182\/blood-2002-06-1774","article-title":"Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors","volume":"101","author":"Tehranchi","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2023122816270914400_bib34","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S2352-3026(17)30228-4","article-title":"Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial","volume":"5","author":"Mittelman","year":"2018","journal-title":"Lancet Haematol"},{"issue":"25","key":"2023122816270914400_bib35","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1182\/blood-2018-06-855221","article-title":"Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia","volume":"132","author":"Dickinson","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2023122816270914400_bib36","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.3324\/haematol.2020.249995","article-title":"Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome","volume":"105","author":"Vicente","year":"2020","journal-title":"Haematologica"},{"issue":"6","key":"2023122816270914400_bib37","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/bjh.14792","article-title":"Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy","volume":"178","author":"Fenaux","year":"2017","journal-title":"Br J Haematol"},{"issue":"4","key":"2023122816270914400_bib38","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.3512","article-title":"Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis","volume":"20","author":"Suragani","year":"2014","journal-title":"Nat Med"},{"issue":"10","key":"2023122816270914400_bib39","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","article-title":"Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study","volume":"18","author":"Platzbecker","year":"2017","journal-title":"Lancet Oncol"},{"issue":"33","key":"2023122816270914400_bib40","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.21.02476","article-title":"Long-term efficacy and safety of luspatercept for anemia treatment in patients with lower-risk myelodysplastic syndromes: the phase II PACE-MDS Study","volume":"40","author":"Platzbecker","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023122816270914400_bib41","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2023122816270914400_bib42","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1007\/s00277-022-04993-7","article-title":"Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes","volume":"101","author":"Mathieu","year":"2022","journal-title":"Ann Hematol"},{"issue":"10399","key":"2023122816270914400_bib43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","article-title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial","volume":"402","author":"Platzbecker","year":"2023","journal-title":"Lancet"},{"issue":"15","key":"2023122816270914400_bib44","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2007.11.9214","article-title":"Factors affecting response and survival in patients with\u00a0myelodysplasia treated with immunosuppressive therapy","volume":"26","author":"Sloand","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2023122816270914400_bib45","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/bloodadvances.2018019414","article-title":"The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2023122816270914400_bib46","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3324\/haematol.2019.219345","article-title":"Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis","volume":"105","author":"Stahl","year":"2020","journal-title":"Haematologica"},{"issue":"14","key":"2023122816270914400_bib47","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"2023122816270914400_bib48","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A\u00a0randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"issue":"7559","key":"2023122816270914400_bib49","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS","volume":"523","author":"Kronke","year":"2015","journal-title":"Nature"},{"issue":"11","key":"2023122816270914400_bib50","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1056\/NEJMoa0912228","article-title":"Persistent malignant stem cells in del(5q) myelodysplasia in remission","volume":"363","author":"Tehranchi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"2023122816270914400_bib51","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression","volume":"29","author":"Jadersten","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2023122816270914400_bib52","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","volume":"140","author":"Sperling","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2023122816270914400_bib53","doi-asserted-by":"crossref","first-page":"e741","DOI":"10.1097\/HS9.0000000000000741","article-title":"Real-world data from the Swiss lenalidomide in MDS del(5q) (SLIM)-Registry identify new chances and challenges in lenalidomide treatment of patients with MDS del(5q)","volume":"6","author":"Rufer","year":"2022","journal-title":"Hemasphere"},{"issue":"2","key":"2023122816270914400_bib54","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/bjh.12876","article-title":"Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion","volume":"166","author":"Sanchez-Garcia","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"2023122816270914400_bib55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.20.01895","article-title":"Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study","volume":"39","author":"Steensma","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 3","key":"2023122816270914400_bib56","doi-asserted-by":"crossref","first-page":"e0568592","DOI":"10.1097\/01.HS9.0000967572.05685.92","article-title":"Continuous transfusion independence with imetelstat in heavily transfused non-del(5q) lower risk myelodysplastic syndromes relapsed\/refractory to erythropoiesis stimulating agents in imerge phase 3","volume":"7","author":"Platzbecker","year":"2023","journal-title":"Hemasphere"},{"issue":"5","key":"2023122816270914400_bib57","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1200\/JCO.2010.31.0854","article-title":"Hypomethylating agents and other novel strategies in myelodysplastic syndromes","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2023122816270914400_bib58","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","article-title":"Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group","volume":"29","author":"Lubbert","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2023122816270914400_bib59","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023122816270914400_bib60","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"1","key":"2023122816270914400_bib61","doi-asserted-by":"crossref","first-page":"60","DOI":"10.6004\/jnccn.2017.0007","article-title":"Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Greenberg","year":"2017","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"36","key":"2023122816270914400_bib62","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.2217\/fon-2021-0936","article-title":"Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?","volume":"17","author":"Zeidan","year":"2021","journal-title":"Future Oncol"},{"issue":"26","key":"2023122816270914400_bib63","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"2023122816270914400_bib64","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1200\/JCO.20.02619","article-title":"Phase III, randomized, placebo-controlled trial of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes","volume":"39","author":"Garcia-Manero","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023122816270914400_bib65","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2008.17.1058","article-title":"Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes","volume":"27","author":"Lyons","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"2023122816270914400_bib66","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1200\/JCO.2012.44.6823","article-title":"Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes","volume":"31","author":"Garcia-Manero","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2023122816270914400_bib67","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/bloodadvances.2022009564","article-title":"Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms","volume":"7","author":"Nannya","year":"2023","journal-title":"Blood Adv"},{"issue":"24","key":"2023122816270914400_bib68","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117","volume":"35","author":"Sekeres","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"2023122816270914400_bib69","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML","volume":"6","author":"Ades","year":"2022","journal-title":"Blood Adv"},{"issue":"15","key":"2023122816270914400_bib70","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"2023122816270914400_bib117","unstructured":"Gilead Sciences, Inc\n          . Gilead to discontinue phase 3 ENHANCE study of magrolimab plus acacitidine in higher-risk MDS. https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2023\/7\/gilead-to-discontinue-phase-3-enhance-study-of-magrolimab-plus-azacitidine-in-higher-risk-mds."},{"issue":"13","key":"2023122816270914400_bib71","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1182\/bloodadvances.2020001482","article-title":"Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure","volume":"4","author":"Ball","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"2023122816270914400_bib72","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1016\/S2352-3026(22)00216-2","article-title":"Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study","volume":"9","author":"Bazinet","year":"2022","journal-title":"Lancet Haematol"},{"issue":"51","key":"2023122816270914400_bib73","doi-asserted-by":"crossref","first-page":"88904","DOI":"10.18632\/oncotarget.21492","article-title":"Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes","volume":"8","author":"Asayama","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"2023122816270914400_bib74","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/bloodadvances.2022008378","article-title":"Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome","volume":"7","author":"DiNardo","year":"2023","journal-title":"Blood Adv"},{"issue":"14","key":"2023122816270914400_bib75","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023122816270914400_bib76","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1046\/j.1365-2141.1997.2973114.x","article-title":"Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders","volume":"98","author":"Wattel","year":"1997","journal-title":"Br J Haematol"},{"issue":"7","key":"2023122816270914400_bib77","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.leukres.2014.03.012","article-title":"Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine","volume":"38","author":"Bally","year":"2014","journal-title":"Leuk Res"},{"issue":"8","key":"2023122816270914400_bib78","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1182\/blood.V98.8.2326","article-title":"Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS","volume":"98","author":"de Witte","year":"2001","journal-title":"Blood"},{"issue":"8","key":"2023122816270914400_bib79","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clml.2022.02.008","article-title":"Current status of CPX-351 therapy in acute myeloid leukemia and myelodysplastic syndrome","volume":"22","author":"Alotaibi","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2023122816270914400_bib80","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A\u00a0decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"issue":"7","key":"2023122816270914400_bib81","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23458","article-title":"Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome","volume":"88","author":"Alessandrino","year":"2013","journal-title":"Am J Hematol"},{"issue":"7","key":"2023122816270914400_bib82","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/leu.2015.37","article-title":"HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM","volume":"29","author":"Robin","year":"2015","journal-title":"Leukemia"},{"issue":"30","key":"2023122816270914400_bib83","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.20.03380","article-title":"Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome","volume":"39","author":"Nakamura","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"2023122816270914400_bib84","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1200\/JCO.20.02724","article-title":"Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study)","volume":"39","author":"Kroger","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023122816270914400_bib85","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jamaoncol.2019.5140","article-title":"Comparison of patient age groups in transplantation for myelodysplastic syndrome: the Medicare Coverage With Evidence Development study","volume":"6","author":"Atallah","year":"2020","journal-title":"JAMA Oncol"},{"issue":"15","key":"2023122816270914400_bib86","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1089\/scd.2017.0031","article-title":"A\u00a0randomized study comparing stem cell transplantation versus conventional therapy for low- and intermediate-risk myelodysplastic syndromes patients","volume":"26","author":"Yu","year":"2017","journal-title":"Stem Cells Dev"},{"issue":"2","key":"2023122816270914400_bib87","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/bmt.2016.266","article-title":"Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT","volume":"52","author":"Robin","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2023122816270914400_bib88","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1200\/JCO.2013.50.3102","article-title":"Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905","volume":"32","author":"Prebet","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023122816270914400_bib89","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jtct.2022.11.014","article-title":"Hematopoietic cell transplantation in the management of myelodysplastic syndrome: an evidence-based review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines","volume":"29","author":"DeFilipp","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"2023122816270914400_bib90","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3324\/haematol.2014.106880","article-title":"Impact of the international prognostic scoring system cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party","volume":"99","author":"Onida","year":"2014","journal-title":"Haematologica"},{"issue":"4","key":"2023122816270914400_bib91","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/leu.2012.297","article-title":"Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia","volume":"27","author":"van Gelder","year":"2013","journal-title":"Leukemia"},{"issue":"30","key":"2023122816270914400_bib92","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1200\/JCO.2016.67.3616","article-title":"Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation","volume":"34","author":"Della Porta","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023122816270914400_bib93","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"2023122816270914400_bib94","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2023122816270914400_bib95","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41375-023-01820-4","article-title":"Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M","volume":"37","author":"Gurnari","year":"2023","journal-title":"Leukemia"},{"issue":"15","key":"2023122816270914400_bib96","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.22.01784","article-title":"Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes","volume":"41","author":"Sauta","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"28","key":"2023122816270914400_bib97","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1200\/JCO.23.00866","article-title":"Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 study","volume":"41","author":"Versluis","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2023122816270914400_bib98","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood-2018-10-844662","article-title":"Genetic predisposition to MDS: clinical features and clonal evolution","volume":"133","author":"Kennedy","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2023122816270914400_bib99","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bbmt.2019.10.015","article-title":"Role of age and hematopoietic cell transplantation-specific comorbidity index in myelodysplastic patients undergoing an allotransplant: a retrospective study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Carre","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2023122816270914400_bib100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41409-021-01502-8","article-title":"Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT","volume":"57","author":"Penack","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"2023122816270914400_bib101","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"de Witte","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2023122816270914400_bib102","doi-asserted-by":"crossref","first-page":"101332","DOI":"10.1016\/j.beha.2021.101332","article-title":"Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome","volume":"34","author":"Niederwieser","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"2023122816270914400_bib103","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood-2005-11-4503","article-title":"Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes","volume":"108","author":"Martino","year":"2006","journal-title":"Blood"},{"issue":"19","key":"2023122816270914400_bib104","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial)","volume":"35","author":"Kroger","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023122816270914400_bib105","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023122816270914400_bib106","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","article-title":"Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): a randomised, non-inferiority, phase\u00a03\u00a0trial","volume":"7","author":"Beelen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"11","key":"2023122816270914400_bib107","doi-asserted-by":"crossref","first-page":"921.e1","DOI":"10.1016\/j.jtct.2021.08.007","article-title":"Fludarabine and melphalan compared with reduced doses of busulfan and fludarabine improve transplantation outcomes in older patients with myelodysplastic syndromes","volume":"27","author":"Oran","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2023122816270914400_bib108","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/bloodadvances.2020003654","article-title":"Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors","volume":"5","author":"Grunwald","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"2023122816270914400_bib109","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1804714","article-title":"Mutation clearance after transplantation for myelodysplastic syndrome","volume":"379","author":"Duncavage","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"2023122816270914400_bib110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/01.HS9.0000843560.87168.a9","article-title":"S167: prediction of relapse after allogeneic stem cell transplantation using individualized measurable residual disease markers; the prospective Nordic study NMDSG14B","volume":"6","author":"Tobiasson","year":"2022","journal-title":"HemaSphere"},{"issue":"21","key":"2023122816270914400_bib111","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A\u00a0phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"issue":"34","key":"2023122816270914400_bib112","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes","volume":"40","author":"Mishra","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"2023122816270914400_bib113","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/bloodadvances.2022008632","article-title":"Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies","volume":"6","author":"Fathi","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"2023122816270914400_bib114","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"key":"2023122816270914400_bib115","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2022.282570","article-title":"Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of\u00a0myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial","author":"Schroeder","year":"2023","journal-title":"Haematologica"},{"issue":"3","key":"2023122816270914400_bib116","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000528184","article-title":"On behalf of the SFGM-TC: prophylactic donor lymphocyte infusion in patients treated with allogeneic stem-cell transplantation for high-risk myelodysplastic syndrome and acute myeloid leukemia","volume":"146","author":"Guisnel","year":"2023","journal-title":"Acta Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/26\/2268\/2178041\/blood_bld-2023-020079-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/26\/2268\/2178041\/blood_bld-2023-020079-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T11:28:19Z","timestamp":1703762899000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/26\/2268\/498409\/Clinical-decision-making-and-treatment-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":120,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2023,12,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023020079","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,28]]}}}